94 related articles for article (PubMed ID: 38589406)
1. Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma.
Bai X; Attrill GH; Gide TN; Ferguson PM; Nahar KJ; Shang P; Vergara IA; Palendira U; da Silva IP; Carlino MS; Menzies AM; Long GV; Scolyer RA; Wilmott JS; Quek C
Nat Commun; 2024 Apr; 15(1):3014. PubMed ID: 38589406
[TBL] [Abstract][Full Text] [Related]
2. Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma.
Petrova V; Arkhypov I; Weber R; Groth C; Altevogt P; Utikal J; Umansky V
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32235439
[TBL] [Abstract][Full Text] [Related]
3. Immune-Related Toxicity Among Adolescent and Young Adult with Melanoma as Compared with the Elderly.
Darwin A; Skinner A; Reed DR; Tanvetyanon T
J Adolesc Young Adult Oncol; 2022 Dec; 11(6):550-555. PubMed ID: 35100046
[No Abstract] [Full Text] [Related]
4. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
Front Immunol; 2021; 12():799455. PubMed ID: 35069581
[TBL] [Abstract][Full Text] [Related]
5. Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma.
Liu D; Yang X; Wu X
Front Immunol; 2021; 12():663495. PubMed ID: 34025664
[TBL] [Abstract][Full Text] [Related]
6. Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma.
Krebs FK; Trzeciak ER; Zimmer S; Özistanbullu D; Mitzel-Rink H; Meissner M; Grabbe S; Loquai C; Tuettenberg A
Cancer Med; 2021 Mar; 10(5):1562-1575. PubMed ID: 33449393
[TBL] [Abstract][Full Text] [Related]
7. Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach.
Mao Y; Gide TN; Adegoke NA; Quek C; Maher N; Potter A; Patrick E; Saw RPM; Thompson JF; Spillane AJ; Shannon KF; Carlino MS; Lo SN; Menzies AM; da Silva IP; Long GV; Scolyer RA; Wilmott JS
J Transl Med; 2023 Apr; 21(1):257. PubMed ID: 37055772
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma.
Wong SK; Blum SM; Sun X; Da Silva IP; Zubiri L; Ye F; Bai K; Zhang K; Ugurel S; Zimmer L; Livingstone E; Schadendorf D; Serra-Bellver P; Muñoz-Couselo E; Ortiz C; Lostes J; Huertas RM; Arance A; Pickering L; Long GV; Carlino MS; Buchbinder EI; Vázquez-Cortés L; Jara-Casas D; Márquez-Rodas I; González-Espinoza IR; Balko JM; Menzies AM; Sullivan RJ; Johnson DB
Eur J Cancer; 2023 Mar; 181():188-197. PubMed ID: 36680880
[TBL] [Abstract][Full Text] [Related]
9. Genomic disparities between cancers in adolescent and young adults and in older adults.
Wang X; Langevin AM; Houghton PJ; Zheng S
Nat Commun; 2022 Nov; 13(1):7223. PubMed ID: 36433963
[TBL] [Abstract][Full Text] [Related]
10. Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
Attrill GH; Owen CN; Ahmed T; Vergara IA; Colebatch AJ; Conway JW; Nahar KJ; Thompson JF; Pires da Silva I; Carlino MS; Menzies AM; Lo S; Palendira U; Scolyer RA; Long GV; Wilmott JS
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688560
[TBL] [Abstract][Full Text] [Related]
11. Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma.
Yaseen Z; Gide TN; Conway JW; Potter AJ; Quek C; Hong AM; Long GV; Scolyer RA; Wilmott JS
Front Mol Biosci; 2022; 9():810858. PubMed ID: 35664673
[TBL] [Abstract][Full Text] [Related]
12. A T cell resilience model associated with response to immunotherapy in multiple tumor types.
Zhang Y; Vu T; Palmer DC; Kishton RJ; Gong L; Huang J; Nguyen T; Chen Z; Smith C; Livák F; Paul R; Day CP; Wu C; Merlino G; Aldape K; Guan XY; Jiang P
Nat Med; 2022 Jul; 28(7):1421-1431. PubMed ID: 35501486
[TBL] [Abstract][Full Text] [Related]
13. Protein-based classification of melanoma differentiation subtypes.
Lim SY; Pedersen B; Rizos H
Pigment Cell Melanoma Res; 2022 Jul; 35(4):471-473. PubMed ID: 35452161
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
